| Patient | Samuel Langhorne Clemens |
|---|---|
| Date of birth | 1956-11-30 |
| Identifiers | MRN HR-NI013-SYN; SSN (made up) 000-13-2964 |
| Document date | 2026-11-01 |
| Author | Winifred Achterberg-Lowe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care a year after his wife's death: yearning, poor sleep, low mood and withdrawal, suicide risk, heavy cigar smoking, chest tightness on hills, gout and cardiovascular risk. Concerns: He says the year since his wife died has not softened anything, and he wants to be able to work and see his friends again; He does not want to give up cigars, which he says help him write, but worries about his heart; He wants the gout attacks to stop. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days | One tablet daily on days 1 to 3, then twice daily on days 4 to 7 | Oral route | 2026-07-17 to 2026-07-24 | completed | S |
| Varenicline 1 mg oral tablet, one tablet twice daily with food for twelve weeks, with a quit date in the second week | One tablet twice daily with food | Oral route | 2026-07-24 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-07-17 | active | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet daily | Oral route | 2026-07-17 | active | S |
| Allopurinol 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-07-17 to 2026-09-11 | completed | S |
| Allopurinol 100 mg oral tablet, two tablets daily (200 mg) | Two tablets daily | Oral route | 2026-09-11 to 2026-10-16 | completed | S |
| Allopurinol 300 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-10-16 | active | S |
| Colchicine 0.6 mg oral tablet, one tablet daily for flare prevention while allopurinol is started, for three to six months | One tablet daily | Oral route | 2026-07-17 | active | S |
| Prednisone 20 mg oral tablet, two tablets (40 mg) each morning for five days, for a gout flare, prescribed by a doctor where he was staying | Two tablets each morning for five days | Oral route | 2026-08-12 to 2026-08-16 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Resting 12-lead electrocardiogram: sinus rhythm at 80 per minute, normal axis and intervals, no Q waves or ST-segment changes | 2026-06-12 to 2026-06-12 | completed | S |
| CT coronary angiography with calcium scoring: coronary calcium score 410; 25 to 49 percent narrowing of the proximal left anterior descending artery from mixed plaque (CAD-RADS 2); no obstructive disease | 2026-07-17 to 2026-07-17 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-09-25 to 2026-09-25 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-09-25 | High-dose influenza vaccine for the coming season | completed | S |
| 2026-09-25 | Pneumococcal conjugate vaccine (PCV20); no earlier pneumococcal vaccine | completed | S |
| 2026-10-16 | RSV vaccine, single dose, for an adult aged 60 to 74 with coronary disease | completed | S |
| 2026-10-16 | Recombinant zoster vaccine, first of two doses | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| June 1872 | Death of his son at about two, from diphtheria | D (CLM-0004) |
| 1894 to 1896 | Bankruptcy after the failure of his publishing company, followed by a worldwide lecture tour to repay his debts | D (CLM-0005) |
| about 1894 and 1897 | Gout: a first attack in Paris and a further attack in Vienna three years later | D (CLM-0010) |
| August 1896 | Death of his eldest daughter at 24, from meningitis | D (CLM-0006) |
| June 5, 1904 | Death of his wife after 22 months of illness, a year before the index visit | D (CLM-0007) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He says the year since his wife died has not softened anything, and he wants to be able to work and see his friends again | active | S |
| He does not want to give up cigars, which he says help him write, but worries about his heart | active | S |
| He wants the gout attacks to stop | active | S |
Most recent measures: Leukocytes [#/volume] in Blood by Automated count 8.1 on 2026-06-12; Hemoglobin [Mass/volume] in Blood 15.6 on 2026-06-12; Platelets [#/volume] in Blood by Automated count 232 on 2026-06-12; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-10-16; Potassium [Moles/volume] in Serum or Plasma 4.4 on 2026-10-16; Creatinine [Mass/volume] in Serum or Plasma 1.09 on 2026-10-16; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 73 on 2026-10-16; Glucose [Mass/volume] in Serum or Plasma 96 on 2026-10-16; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 28 on 2026-09-11; Urate [Mass/volume] in Serum or Plasma 6.4 on 2026-10-16; Hemoglobin A1c/Hemoglobin.total in Blood 5.8 on 2026-06-12; Cholesterol [Mass/volume] in Serum or Plasma 156 on 2026-09-11; Cholesterol in HDL [Mass/volume] in Serum or Plasma 46 on 2026-09-11; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 74 on 2026-09-11; Triglyceride [Mass/volume] in Serum or Plasma 180 on 2026-09-11; Thyrotropin [Units/volume] in Serum or Plasma 2.2 on 2026-06-12; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 410 on 2026-06-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 on 2026-10-16; Total score [AUDIT-C] 3 on 2026-06-12; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-09-25; Total score [Mini-Cog] 5 on 2026-09-25 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Persistent yearning for his wife, broken sleep, low mood and withdrawal from friends and work, a year after her death; cause under evaluation | resolved | confirmed | Z63.4 | S — Synthetic presenting problem anchored to his wife's documented death a year before; resolved into the diagnosis of prolonged grief disorder at the consultation. Not a claim about his real grief. |
| Prolonged grief disorder (DSM-5-TR): more than 12 months after his wife's death, daily yearning and preoccupation with her, with intense emotional pain, a sense that part of himself has died, avoidance of reminders, loneliness, difficulty taking up his work and life again, and a feeling that life is meaningless; PG-13-R 41; major depression not present | active | confirmed | F43.81 | S — Synthetic modern diagnosis made at the consultation, anchored to his documented bereavements. Not a claim about his real mental health; the roster's bipolar lead is not used. |
| Tobacco use disorder, cigars: about fifteen cigars a day, smoking since boyhood, some smoke inhaled; first cigar within thirty minutes of waking | active | confirmed | F17.290 | S — Synthetic modern coding anchored to his documented smoking since boyhood. |
| Chest tightness on climbing steep hills, twice in the past month, easing within five minutes of rest; none at rest; cause under evaluation | resolved | confirmed | R07.89 | S — Synthetic presenting symptom; resolved into a diagnosis at five weeks after CT coronary angiography. Not a claim about his real heart in 1905; his documented chest pain began in 1909. |
| Coronary artery disease, nonobstructive (CAD-RADS 2: 25 to 49 percent narrowing of the proximal left anterior descending artery; coronary calcium score 410), with exertional chest tightness that has not recurred on treatment; treated with a statin, aspirin and stopping smoking | active | confirmed | I25.10 | S — Synthetic modern diagnosis made at five weeks. Not a claim about his real coronary arteries. |
| Gout, recurrent flares of the big toe since his late fifties, two in the past year; serum urate 8.6 mg/dL; no tophi | active | confirmed | M10.9 | S — Synthetic modern diagnosis anchored to his documented gout. |
| Acute bronchitis, likely viral, for six days in a cigar smoker; no pneumonia on examination; resolved within three weeks without antibiotics | resolved | confirmed | J20.9 | S — Synthetic acute illness; not a historical claim; his documented bronchitis was in later years. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-12 | Leukocytes [#/volume] in Blood by Automated count | 8.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-12 | Hemoglobin [Mass/volume] in Blood | 15.6 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-06-12 | Platelets [#/volume] in Blood by Automated count | 232 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-12 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-12 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-12 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-06-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 74 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-12 | Glucose [Mass/volume] in Serum or Plasma | 101 | mg/dL | 70-99 mg/dL | High | S |
| 2026-06-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-56 U/L | Normal | S |
| 2026-06-12 | Urate [Mass/volume] in Serum or Plasma | 8.6 | mg/dL | 3.5-7.2 mg/dL | High | S |
| 2026-06-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.8 | % | <=5.6% | High | S |
| 2026-06-12 | Cholesterol [Mass/volume] in Serum or Plasma | 228 | mg/dL | <=199 mg/dL | High | S |
| 2026-06-12 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-06-12 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 150 | mg/dL | <=99 mg/dL | High | S |
| 2026-06-12 | Triglyceride [Mass/volume] in Serum or Plasma | 170 | mg/dL | <=149 mg/dL | High | S |
| 2026-06-12 | Thyrotropin [Units/volume] in Serum or Plasma | 2.2 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-06-12 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 410 | pg/mL | 200-900 pg/mL | Normal | S |
| 2026-06-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 11 | {score} | S | ||
| 2026-06-12 | Total score [AUDIT-C] | 3 | {score} | S | ||
| 2026-07-17 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S | ||
| 2026-09-11 | Cholesterol [Mass/volume] in Serum or Plasma | 156 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-09-11 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-09-11 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 74 | mg/dL | <=99 mg/dL | Normal | S |
| 2026-09-11 | Triglyceride [Mass/volume] in Serum or Plasma | 180 | mg/dL | <=149 mg/dL | High | S |
| 2026-09-11 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-56 U/L | Normal | S |
| 2026-09-11 | Urate [Mass/volume] in Serum or Plasma | 7.4 | mg/dL | 3.5-7.2 mg/dL | High | S |
| 2026-09-11 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-11 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-11 | Creatinine [Mass/volume] in Serum or Plasma | 1.1 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-09-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 73 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-09-11 | Glucose [Mass/volume] in Serum or Plasma | 98 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-11 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-10-16 | Urate [Mass/volume] in Serum or Plasma | 6.4 | mg/dL | 3.5-7.2 mg/dL | Normal | S |
| 2026-10-16 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-16 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-16 | Creatinine [Mass/volume] in Serum or Plasma | 1.09 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-10-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 73 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-16 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-10-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-09-25 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-09-25 | Total score [Mini-Cog] | 5 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-12 | Body height | 173 | cm | S |
| 2026-06-12 | Body weight | 64 | kg | S |
| 2026-06-12 | Body mass index (BMI) [Ratio] | 21.4 | kg/m2 | S |
| 2026-06-12 | Systolic blood pressure | 142 | mm[Hg] | S |
| 2026-06-12 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-06-12 | Heart rate | 82 | /min | S |
| 2026-06-12 | Respiratory rate | 16 | /min | S |
| 2026-06-12 | Body temperature | 36.6 | Cel | S |
| 2026-06-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 2026-06-19 | Body height | 173 | cm | S |
| 2026-06-19 | Body weight | 63.8 | kg | S |
| 2026-06-19 | Body mass index (BMI) [Ratio] | 21.3 | kg/m2 | S |
| 2026-06-19 | Systolic blood pressure | 138 | mm[Hg] | S |
| 2026-06-19 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-06-19 | Heart rate | 80 | /min | S |
| 2026-06-19 | Respiratory rate | 16 | /min | S |
| 2026-06-19 | Body temperature | 36.7 | Cel | S |
| 2026-06-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 2026-07-17 | Body height | 173 | cm | S |
| 2026-07-17 | Body weight | 64.1 | kg | S |
| 2026-07-17 | Body mass index (BMI) [Ratio] | 21.4 | kg/m2 | S |
| 2026-07-17 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-07-17 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-07-17 | Heart rate | 78 | /min | S |
| 2026-07-17 | Respiratory rate | 16 | /min | S |
| 2026-07-17 | Body temperature | 36.6 | Cel | S |
| 2026-07-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 2026-09-11 | Body height | 173 | cm | S |
| 2026-09-11 | Body weight | 64.9 | kg | S |
| 2026-09-11 | Body mass index (BMI) [Ratio] | 21.7 | kg/m2 | S |
| 2026-09-11 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-09-11 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-09-11 | Heart rate | 72 | /min | S |
| 2026-09-11 | Respiratory rate | 14 | /min | S |
| 2026-09-11 | Body temperature | 36.6 | Cel | S |
| 2026-09-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-10-16 | Body height | 173 | cm | S |
| 2026-10-16 | Body weight | 65.4 | kg | S |
| 2026-10-16 | Body mass index (BMI) [Ratio] | 21.9 | kg/m2 | S |
| 2026-10-16 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-10-16 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-16 | Heart rate | 70 | /min | S |
| 2026-10-16 | Respiratory rate | 14 | /min | S |
| 2026-10-16 | Body temperature | 36.6 | Cel | S |
| 2026-10-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-09-25 | Body height | 173 | cm | S |
| 2026-09-25 | Body weight | 65.1 | kg | S |
| 2026-09-25 | Body mass index (BMI) [Ratio] | 21.8 | kg/m2 | S |
| 2026-09-25 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-09-25 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-25 | Heart rate | 70 | /min | S |
| 2026-09-25 | Respiratory rate | 14 | /min | S |
| 2026-09-25 | Body temperature | 36.6 | Cel | S |
| 2026-09-25 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-07-31 | Body height | 173 | cm | S |
| 2026-07-31 | Body weight | 63.9 | kg | S |
| 2026-07-31 | Body mass index (BMI) [Ratio] | 21.4 | kg/m2 | S |
| 2026-07-31 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-07-31 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-07-31 | Heart rate | 86 | /min | S |
| 2026-07-31 | Respiratory rate | 18 | /min | S |
| 2026-07-31 | Body temperature | 37.5 | Cel | S |
| 2026-07-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-06-12 | Establishing primary care a year after his wife's death: yearning, poor sleep, low mood and withdrawal, suicide risk, heavy cigar smoking, chest tightness on hills, gout and cardiovascular risk | finished | S |
| 2026-06-19 | One-week review, seen the same day by geriatric psychiatry: the diagnosis of prolonged grief disorder, grief therapy, sleep and safety | finished | S |
| 2026-07-17 | Five-week review: CT coronary angiography result, a statin and aspirin, a plan to quit smoking, and starting allopurinol | finished | S |
| 2026-09-11 | Thirteen-week review: grief therapy, smoking, a gout flare while away, the urate and lipid results | finished | S |
| 2026-10-16 | Eighteen-week review: grief, no smoking, urate toward target and his writing | finished | S |
| 2026-09-25 | Subsequent annual wellness visit | finished | S |
| 2026-07-31 | Same-day sick visit for a cough | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Geriatric psychiatry consultation to confirm the diagnosis, separate prolonged grief disorder from major depression, advise on grief therapy, medicine and sleep, and review suicide risk | completed | GL-APA-PGD, GL-PG13R-2021, GL-SUICIDE-2024 | S |
| Safety: a structured safety assessment, a written safety plan, the 988 Suicide & Crisis Lifeline in his phone, means safety, a telephone call in three days, and safety review at every visit | completed | GL-SUICIDE-2024, GL-BEREAVED-MEN-2004, GL-CMID-2026 | S |
| Prolonged grief disorder therapy (Shear): sixteen weekly sessions with a trained psychologist, covering the story of the death, imaginal conversations with his wife, memories and pictures, revisiting avoided places and things, and personal goals; PG-13-R and PHQ-9 every four weeks; no antidepressant unless major depression develops | completed | GL-PGDT-2005, GL-PGDT-2016, GL-APA-PGD, GL-PG13R-2021 | S |
| Sleep: a fixed rising time, no naps after noon, no cigar or whisky in the last hours before bed, and getting up if awake more than twenty minutes; no benzodiazepine, zolpidem or sedating antihistamine | completed | GL-PGDT-2016, GL-CMID-2026 | S |
| Tobacco: his readiness asked at every visit; brief advice linked to his own concern about his heart; counseling at each visit and the state quitline; varenicline offered as the most effective single medicine, with combination nicotine replacement as the alternative | completed | GL-USPSTF-TOB-2021 | S |
| Chest tightness on exertion: resting ECG today and CT coronary angiography, chosen over stress testing for a man over 65 with stable symptoms and no known coronary disease; call 911 for chest pain at rest or lasting more than fifteen minutes | completed | GL-CHESTPAIN-2021 | S |
| Nonobstructive coronary disease: atorvastatin 40 mg with a lipid panel 4 to 12 weeks later and a goal of at least a 50 percent fall in LDL, aspirin 81 mg, blood pressure below 130/80 mmHg, stopping smoking, and walking most days | completed | GL-CCD-2023, GL-CMID-2026 | S |
| Gout: allopurinol from 100 mg daily, raised by 100 mg every two to five weeks to a serum urate below 6 mg/dL, with colchicine 0.6 mg daily for three to six months to prevent flares; flares treated without stopping allopurinol; HLA-B*58:01 testing not indicated by ancestry; less alcohol | completed | GL-ACR-GOUT-2020 | S |
| Social connection and his writing: one planned social contact a week, a return to morning writing on a set project, and the clinic social worker's list of local groups; meaning and goals to be part of any grief treatment | completed | GL-PGDT-2005 | S |
| Gout: urate measured at intake; urate-lowering therapy explained, since two flares in a year make it strongly recommended; he chose to decide after the chest evaluation; call at the first sign of a flare | completed | GL-ACR-GOUT-2020 | S |
| Cardiovascular risk: blood pressure at each visit and lipids, hemoglobin A1c and kidney function at baseline; prediabetes (hemoglobin A1c 5.8 percent) managed with walking and diet | completed | GL-CMID-2026, GL-CHESTPAIN-2021 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| PG-13-R below 30 and back to writing and seeing friends | 2026-10-16 | completed | PG-13-R 41 at intake to 26 at eighteen weeks; finishing a long essay; dinner with friends weekly | S |
| No thoughts of death and a safety plan he would use | 2026-09-11 | completed | Passive thoughts of death at intake; none since the five-week visit; safety plan kept | S |
| Stop smoking cigars | 2026-10-16 | active | Fifteen cigars a day at intake; quit in the first week of August with varenicline; one lapse of two cigars while away; none for eight weeks | S |
| LDL cholesterol at least 50 percent lower on a high-intensity statin | 2026-09-11 | completed | LDL 150 to 74 mg/dL (51 percent lower) at eight weeks | S |
| Serum urate below 6 mg/dL and no gout flares | 2026-10-16 | active | Urate 8.6, 7.4 and 6.4 mg/dL; one flare in August, treated while away; allopurinol raised to 300 mg | S |
| Six or more hours of sleep on most nights without a sleeping pill | 2026-10-16 | completed | About four to five hours at intake; six hours on most nights by eighteen weeks | S |
Structured synthetic safety assessment on 2026-06-12: current ideation present, intent absent, plan absent. Outpatient care with weekly visits and a telephone call in three days. Passive thoughts of death (wishing he could join his wife) without intent, plan or preparation; no past suicide attempt. Older widowed men are at high risk of suicide in the years after a loss (a Danish register study found the highest rise in suicide risk in the oldest bereaved men), and he has several further risk factors: repeated bereavement, living through the anniversary of her death, insomnia, alcohol each evening, chronic illness and social withdrawal. Means safety: no firearms in the house; medicines kept in small supplies; he agreed to keep whisky to one glass and none on bad nights. A written safety plan was made with him, and the 988 Suicide & Crisis Lifeline (call or text 988) was saved in his phone. Safety is reviewed at every visit [S]